NCT07095075 - A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Relapsed/Refractory Autoimmune Diseases

Interventions

BIOLOGICAL

LUCAR-DKS1 NK cells

Prior to the infusion of the LUCAR-DKS1 cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

Trial Locations (5)

210029

Jiangsu Province Hospital, Nanjing

215006

The First Affiliated Hospital of Soochow University, Suzhou

230036

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei

233000

The Third The People's Hospital of BengBu, Bengbu

325015

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou